Jacobs Levy Equity Management Inc. Has $688,000 Stock Holdings in CryoPort, Inc. $CYRX

Key Points

• Jacobs Levy Equity Management Inc. increased its stake in CryoPort by 54%, acquiring an additional 39,698 shares, bringing its total holdings to 113,235 shares valued at approximately $688,000.
• A significant number of other institutional investors have also increased their stakes in CryoPort, with 92.90% of the stock currently owned by institutional investors.
• In recent transactions, insiders such as Director Robert J. Hariri and CEO Jerrell Shelton sold significant shares, resulting in a total of 449,413 shares being sold by insiders in the last ninety days.

Jacobs Levy Equity Management Inc. increased its stake in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 54.0% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 113,235 shares of the company's stock after acquiring an additional 39,698 shares during the period. Jacobs Levy Equity Management Inc. owned 0.23% of CryoPort worth $688,000 as of its most recent filing with the SEC.

Other institutional investors also recently added to or reduced their stakes in the company. Millennium Management LLC raised its position in CryoPort by 11.0% in the 4th quarter. Millennium Management LLC now owns 4,139,869 shares of the company's stock valued at $32,208,000 after purchasing an additional 409,353 shares during the last quarter. Deutsche Bank AG boosted its stake in shares of CryoPort by 0.9% during the 4th quarter. Deutsche Bank AG now owns 1,397,121 shares of the company's stock worth $10,870,000 after acquiring an additional 12,864 shares during the period. Silvercrest Asset Management Group LLC increased its stake in shares of CryoPort by 77.0% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 742,914 shares of the company's stock worth $5,780,000 after purchasing an additional 323,216 shares during the period. Readystate Asset Management LP grew its position in CryoPort by 91.6% during the first quarter. Readystate Asset Management LP now owns 500,344 shares of the company's stock worth $3,042,000 after buying an additional 239,153 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its holdings in shares of CryoPort by 20.1% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 408,385 shares of the company's stock valued at $3,177,000 after purchasing an additional 68,474 shares in the last quarter. 92.90% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Robert J. Hariri sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $9.71, for a total value of $242,750.00. Following the completion of the sale, the director directly owned 51,275 shares in the company, valued at approximately $497,880.25. The trade was a 32.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ramkumar Mandalam sold 40,728 shares of the company's stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $7.24, for a total transaction of $294,870.72. Following the completion of the transaction, the director owned 92,328 shares of the company's stock, valued at $668,454.72. This trade represents a 30.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 178,828 shares of company stock worth $1,317,324. Corporate insiders own 10.00% of the company's stock.

CryoPort Price Performance

Shares of CYRX stock traded up $1.18 on Thursday, reaching $10.05. 1,024,087 shares of the company were exchanged, compared to its average volume of 571,540. CryoPort, Inc. has a 1 year low of $4.58 and a 1 year high of $10.46. The company has a market cap of $503.20 million, a price-to-earnings ratio of 7.56 and a beta of 1.62. The company has a debt-to-equity ratio of 0.39, a quick ratio of 15.47 and a current ratio of 16.24. The business has a 50-day moving average price of $8.37 and a 200 day moving average price of $7.00.

CryoPort (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.09). CryoPort had a negative return on equity of 9.79% and a net margin of 37.21%.The company had revenue of $45.45 million during the quarter, compared to analyst estimates of $41.74 million. CryoPort has set its FY 2025 guidance at EPS. Equities research analysts forecast that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Leerink Partnrs raised CryoPort from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, August 6th. Leerink Partners upgraded shares of CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 target price for the company in a research report on Wednesday, August 6th. Stephens initiated coverage on shares of CryoPort in a report on Tuesday, July 22nd. They set an "overweight" rating and a $13.00 target price for the company. BTIG Research raised their price target on shares of CryoPort from $10.00 to $15.00 and gave the company a "buy" rating in a research report on Thursday. Finally, KeyCorp upgraded shares of CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 target price on the stock in a research note on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $12.56.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.